Factors affecting outcomes in Crohn's disease over 15 years.
about
The multidisciplinary health care team in the management of stenosis in Crohn's diseaseMeasuring disease activity in Crohn's disease: what is currently available to the clinician.The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.Elevated C-reactive protein is associated with disease progression in patients with mild Crohn's diseaseRisk factors for postoperative recurrence of Crohn's disease.Endoscopic management of inflammatory bowel disease strictures.Recent advances: Personalised use of current Crohn's disease therapeutic options.The cost-effectiveness of infliximab in Crohn's disease.Clinical features and predictors of clinical outcomes in Korean patients with Crohn's disease: a Korean association for the study of intestinal diseases multicenter study.Evolution of Clinical Behavior in Crohn's Disease: Factors Associated with Complicated Disease and Surgery.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.The future developments in inflammatory bowel disease care.Time to Relapse in Children with Crohn's Disease Treated with Azathioprine and Nutritional Therapy or Corticosteroids.Does Crohn's Disease with Concomitant Orofacial Granulomatosis Represent a Distinctive Disease Subtype?Long-term evolution and predictive factors of mild inflammatory bowel disease.Proliferation and apoptosis of Peyer's patches and its lymphocytes in experimental terminal ileitis.Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era.Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn’s disease patients.How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort.Thiopurines and the natural course of Crohn's disease: did we finally find the right therapeutic target?Presentation and progression of childhood-onset inflammatory bowel disease in Northern Stockholm County.Targeting Remission in Moderate-to-Severe Crohn's Disease.Republished: Recent advances: personalised use of current Crohn's disease therapeutic optionsA risk score system to timely manage treatment in Crohn's disease: a cohort study
P2860
Q28088702-D438528B-FAAA-4173-A88E-C3FB5157E6D5Q33668961-6ADEDF1E-61EE-469E-96C7-A413962B1CCAQ36898669-842BCFC4-BEEA-45C8-B573-A81F69CA46B6Q37037524-05DEBA6A-7206-47FC-B433-994E38F2FCF6Q37708313-F0E810A8-47D6-44BB-B63F-15B1128775E8Q38063200-A2764656-F2ED-4713-BC48-68DB8B9E9E4BQ38137830-6ED7FA7A-E3A3-429A-9B31-1DB67E3F63E9Q38241338-D47584A0-CA55-407C-A8A2-DF5756BBD674Q38447501-2B03567E-AB1C-4B3C-AE2E-3CD38130747BQ38658493-E827EAD1-B4B1-4EF3-9AAD-DA09D7789D33Q38826447-021AED84-2781-43EC-9410-2147D3AB01A0Q38976561-C88E5D65-35DD-4F25-88FA-49AF87E532B5Q39353122-C079CE66-F900-4ABA-923C-242907368247Q39594232-0E114DB0-6B9C-43E8-A733-6D62F77E53E5Q39925453-B7C86871-EFB0-408F-A1B7-1ED34C17641BQ40038090-FAC8791F-5D53-498E-B73B-726C39C87BF9Q40056667-EBA79894-D549-406E-A7E0-A7865FD311C8Q42109477-BA8DD2DB-795A-4D8D-99A6-70C9D792FA5BQ44596777-2F9BA5CD-B404-4D7B-81A9-53E2C164A2C0Q50329202-F5EDE08B-0EF9-4FF3-AFFE-84EB54F01F8AQ51058515-53EE246E-A325-4214-B3E1-C578548D15A0Q51070482-A3728BA4-806D-47A5-A069-3C9D8349A6C5Q53554449-94A41083-7F3E-47E4-AEE2-032360763159Q55379779-97424A73-FECD-4088-A3B2-ECB603D131F2Q57265311-68C05538-BC22-4C59-8A25-B262EA80C901Q58605356-240F2587-57BB-4F78-B8FB-CFF03FF06A62
P2860
Factors affecting outcomes in Crohn's disease over 15 years.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Factors affecting outcomes in Crohn's disease over 15 years.
@ast
Factors affecting outcomes in Crohn's disease over 15 years.
@en
type
label
Factors affecting outcomes in Crohn's disease over 15 years.
@ast
Factors affecting outcomes in Crohn's disease over 15 years.
@en
prefLabel
Factors affecting outcomes in Crohn's disease over 15 years.
@ast
Factors affecting outcomes in Crohn's disease over 15 years.
@en
P2093
P2860
P1433
P1476
Factors affecting outcomes in Crohn's disease over 15 years.
@en
P2093
Anne Bourrier
Harry Sokol
Isabelle Nion-Larmurier
Jacques Cosnes
Philippe Seksik
P2860
P304
P356
10.1136/GUTJNL-2011-301971
P407
P577
2012-03-02T00:00:00Z